Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.67 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ACP3 | P15309 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701658 | 1.00 | PDE2A (0.67) | PDE2AADRB2KIF11CES2CES1 | |
| SCHEMBL268077 | 1.00 | PDE2A (0.67) | PDE2AADRB2KIF11CES2CES1 | |
| Bromide SCHEMBL28801001 | 0.98 | PDE2A (0.64) | PDE2AADRB2KIF11CES2CES1 | |
| Hydrochloric Acid SCHEMBL4935636 | 0.98 | PDE2A (0.64) | PDE2AADRB2KIF11CES2CES1 | |
| Hydrochloric Acid SCHEMBL20266800 | 0.98 | PDE2A (0.64) | PDE2AADRB2KIF11CES2CES1 | |
| Iodide SCHEMBL28800992 | 0.98 | PDE2A (0.64) | PDE2AADRB2KIF11CES2CES1 | |
| Hydrochloric Acid SCHEMBL27940422 | 0.98 | PDE2A (0.64) | PDE2AADRB2KIF11CES2CES1 | |
| SCHEMBL30913861 | 0.94 | PDE2A (0.60) | PDE2AADRB2KIF11CASR | |
| SCHEMBL13448214 | 0.88 | PDE2A (0.55) | PDE2AADRB2 | |
| SCHEMBL30828328 | 0.86 | PDE2A (0.52) | PDE2AADRB2KIF11CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577208-B2 | TEAD inhibitors and uses thereof | EHE Foundation (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250368620-A1 | ARNT Degrading Compounds and Uses Thereof | CELGENE CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| WO-2025119351-A1 | GPR139 AGONIST | 深圳湾实验室 | 2025-06-12 | — | — | WO | disclosed |
| CN-119954725-A | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250136552-A1 | ANTAGONISTS OF CAV 2.3 | LARIO THERAPEUTICS LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| EP-4537905-A2 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| US-7368609-B2 | Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20070142670-A1 | Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same | CENTRAL GLASS CO., LTD. (JP) | 2007-06-21 | — | — | US | disclosed |
| US-7186865-B2 | Reacting optically active secondary amine with alkylation agent in presence of a base, thereby converting the secondary amine into an optically active tertiary amine and subjecting the tertiary amine to hydrogenolysis, producing the N-monoalkyl derivative; intermediates for drugs, agriculture | CENTRAL GLASS COMPANY, LIMITED (JP) | 2007-03-06 | — | — | US | disclosed |
| WO-2006116157-A9 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS INC (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006116157-A2 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
| US-7081551-B2 | Optically active (R)-1-(4-trifluoromethylphenyl)ethylamine | CENTRAL GLASS CO., LTD. (JP) | 2006-07-25 | — | — | US | disclosed |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | APPLIED RESEARCH SYSTEMS ARS (NL) | 2005-06-09 | — | — | US | disclosed |
| US-20040235961-A1 | Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| US-20040024253-A1 | Optically active (R)-1- (4-trifluoromethylphenyl) ethylamine | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235961-A1 | Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same | NAT1, PNMT, AFF1 | PDE2A 1807/4885ADRB2 37/4885KIF11 2616/4885 |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ADRM1, SUMO2, BAZ1A | PDE2A 4574/4885ADRB2 2927/4885KIF11 2896/4885 |
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | GPR139, GPR119, GPR39 | PDE2A 414/4885ADRB2 58/4885KIF11 1995/4885 |
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | PDE2A 146/4885ADRB2 119/4885KIF11 1564/4885 |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | PTPRS, PTPA, PTPMT1 | PDE2A 549/4885ADRB2 4414/4885KIF11 3551/4885 |
| US-20040024253-A1 | Optically active (R)-1- (4-trifluoromethylphenyl) ethylamine | HPD, ALDH1A2, DHPS | PDE2A 4147/4885ADRB2 864/4885KIF11 4032/4885 |
| US-20070142670-A1 | Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same | NAT1, AFF1, PNMT | PDE2A 1623/4885ADRB2 45/4885KIF11 2315/4885 |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, VHL, BAZ1A | PDE2A 4681/4885ADRB2 2697/4885KIF11 3164/4885 |
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | PDE2A 1154/4885ADRB2 867/4885KIF11 3833/4885 |
| US-12577208-B2 | TEAD inhibitors and uses thereof | BRCA1, BRAF, MEN1 | PDE2A 2539/4885ADRB2 912/4885KIF11 1501/4885 |
| US-20250136552-A1 | ANTAGONISTS OF CAV 2.3 | CACNA1E, CACNA1A, CACNA1S | PDE2A 2649/4885ADRB2 633/4885KIF11 3609/4885 |
| US-20250368620-A1 | ARNT Degrading Compounds and Uses Thereof | ARNT, AHR, NR1H2 | PDE2A 1438/4885ADRB2 211/4885KIF11 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.